The main problem with people who are HIV+ is access to HAART drugs. Realizing the scope of the private sector, government has to incorporate the private doctors and their influence into all of its drug distribution programs. Today, Indian businesses, such as Cipla, a Mumbai based Drug company, have successfully developed the world’s most cost effective antiretroviral treatments by improving on the manufacturing process of Western – patented triple – therapy dosages. (Luce 346) To further lower the cost, the government can utilize IDPL, a government owned and run pharmaceutical manufacturing company.
 |
|
www.superstock.co.uk/ |
To further expedite the distribution process, the government can utilize the pharmacists of India. India does not differentiate between over the counter or prescription drugs, hence pharmacists too can prescribe drugs. Brochures specifically directed towards pharmacists, informing them about the proper course of HAART medication will first ensure that pharmacists do not prescribe non –effective drugs and second ensure accessibility for those who do not have the resources to approach doctors.
As mentioned before most people in India are uninsured and have to pay for healthcare directly out of their own pocket. This often results in an interrupted adherence patterns in HAART. Since 90 – 95 percent adherence is required for most HAART drugs to be effective, interruptions in treatment can lead to development of multi-drug resistant strains.
Progressive steps have been taken in that direction, in 2004, a national free HAART program was initiated. Even with the stringy requirements to receive free HAART therapy, as of January 31, 2007 about 56,000 patients were receiving treatments at 103 centers. The goal of the government is to have 250 public centers open within 5 years. However, the government can greatly increase its reach if these centers incorporate private doctors and pharmacists into their program.